Mifepristone
- Generic Name
- Mifepristone
- Brand Names
- Korlym, Mifegymiso
- Drug Type
- Small Molecule
- Chemical Formula
- C29H35NO2
- CAS Number
- 84371-65-3
- Unique Ingredient Identifier
- 320T6RNW1F
- Background
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
- Indication
For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
- Associated Conditions
- Hyperglycemia
- Associated Therapies
- Medically induced abortion
Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage
- Conditions
- Silent Miscarriage
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 884
- Registration Number
- NCT06733727
REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism
- Conditions
- Treatment-resistant PTSD
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Christiaan Vinkers
- Target Recruit Count
- 60
- Registration Number
- NCT06689254
- Locations
- 🇳🇱
Amsterdam UMC, location VUmc, Amsterdam, Noord-Holland, Netherlands
Endometrial Transcript Profile with Progesterone After Post-ovulatory Mifepristone
- Conditions
- Endometrial Endocrine RegulationProgesterone Supplementation in Women After Mifepristone
- Interventions
- Drug: Micronized Progesterone 600 mgDrug: Placebo VaginalDrug: Oral Placebo Tablet
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Reproductive Health Research Insritute, Chile
- Target Recruit Count
- 9
- Registration Number
- NCT06616077
- Locations
- 🇨🇱
Hospital San Borja Arriarán, Santiago, Región Metropolitana, Chile
Mifepristone vs Misoprostol
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 94
- Registration Number
- NCT06502158
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Assessing the Efficacy and Acceptability of Two Missed Period Pills Regimens
- Conditions
- Pregnancy RelatedPregnancy Early
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Gynuity Health Projects
- Target Recruit Count
- 286
- Registration Number
- NCT06492889
Efficacy, Safety, and Acceptability of Mifepristone 50 Mg Once-weekly As a Contraceptive
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 1186
- Registration Number
- NCT06394999
- Locations
- 🇳🇱
Noordwest Ziekenhuisgroep, Alkmaar, Netherlands
🇳🇱Flevoziekenhuis, Almere, Netherlands
🇳🇱Admiraal De Ruyter Ziekenhuis, Goes, Netherlands
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 201
- Registration Number
- NCT06099769
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California San Francisco (Data collection only), San Francisco, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone
- Conditions
- Submucous Leiomyoma of Uterus
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Target Recruit Count
- 294
- Registration Number
- NCT05898321
- Locations
- 🇨🇳
Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location
- Conditions
- Abortion
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Planned Parenthood League of Massachusetts
- Target Recruit Count
- 50
- Registration Number
- NCT05839899
- Locations
- 🇺🇸
Planned Parenthood League of Massachusetts, Boston, Massachusetts, United States
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
- Conditions
- HypercortisolismDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 1113
- Registration Number
- NCT05772169
- Locations
- 🇺🇸
Site 407, Escondido, California, United States
🇺🇸Site 379, Gardena, California, United States
🇺🇸Site 378, Huntington Park, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.